SPOTLIGHT: Roche drops out of PDL program

Roche has decided to drop its role as a collaborator in the development of PDL Biopharma's daclizumab in asthma following a portfolio review. It will continue to collaborate, though, on daclizumab in transplant maintenance. PDL, meanwhile, says it will need to find a new partner in order to continue with the asthma program. Report